Millennium Management’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.4M | Buy |
146,639
+70,445
| +92% | +$2.66M | ﹤0.01% | 2501 |
|
|
2025
Q4 | $2.5M | Sell |
76,194
-332,005
| -81% | -$8.68M | ﹤0.01% | 3743 |
|
|
2025
Q3 | $6.84M | Buy |
+408,199
| New | +$6.66M | ﹤0.01% | 2788 |
|
|
2025
Q1 | – | Sell |
-167,804
| Closed | -$3.91M | – | 6388 |
|
|
2024
Q4 | $3.91M | Buy |
+167,804
| New | +$4.92M | ﹤0.01% | 3047 |
|
|
2024
Q2 | – | Sell |
-319,563
| Closed | -$12.1M | – | 6516 |
|
|
2024
Q1 | $12.1M | Buy |
319,563
+211,077
| +195% | +$6.12M | 0.01% | 2009 |
|
|
2023
Q4 | $2.33M | Buy |
108,486
+70,673
| +187% | +$974K | ﹤0.01% | 3485 |
|
|
2023
Q3 | $463K | Sell |
37,813
-60,316
| -61% | -$797K | ﹤0.01% | 4710 |
|
|
2023
Q2 | $1.11M | Sell |
98,129
-51,330
| -34% | -$243K | ﹤0.01% | 3964 |
|
|
2023
Q1 | $1.08M | Buy |
149,459
+24,200
| +19% | +$265K | ﹤0.01% | 4013 |
|
|
2022
Q4 | $1.41M | Buy |
125,259
+92,672
| +284% | +$1.67M | ﹤0.01% | 3851 |
|
|
2022
Q3 | $429K | Buy |
32,587
+11,710
| +56% | +$145K | ﹤0.01% | 5088 |
|
|
2022
Q2 | $264K | Buy |
20,877
+3,920
| +23% | +$137K | ﹤0.01% | 5466 |
|
|
2022
Q1 | $975K | Buy |
16,957
+9,338
| +123% | +$784K | ﹤0.01% | 4549 |
|
|
2021
Q4 | $905K | Sell |
7,619
-13,790
| -64% | -$2.18M | ﹤0.01% | 4502 |
|
|
2021
Q3 | $4.25M | Sell |
21,409
-318
| -1% | -$55.6K | ﹤0.01% | 3049 |
|
|
2021
Q2 | $3.78M | Buy |
21,727
+6,882
| +46% | +$1.25M | ﹤0.01% | 3124 |
|
|
2021
Q1 | $2.94M | Sell |
14,845
-3,521
| -19% | -$676K | ﹤0.01% | 3159 |
|
|
2020
Q4 | $3.61M | Buy |
18,366
+16,186
| +742% | +$3.35M | ﹤0.01% | 2757 |
|
|
2020
Q3 | $386 | Sell |
2,180
-5,158
| -70% | -$954K | ﹤0.01% | 3710 |
|
|
2020
Q2 | $1.7M | Buy |
7,338
+6,781
| +1,217% | +$1.29M | ﹤0.01% | 2643 |
|
|
2020
Q1 | $65K | Buy |
+557
| New | +$94.7K | ﹤0.01% | 3633 |
|
|
2019
Q3 | – | Sell |
-3,035
| Closed | -$520K | – | 4545 |
|
|
2019
Q2 | $520K | Buy |
3,035
+2,454
| +422% | +$424K | ﹤0.01% | 3202 |
|
|
2019
Q1 | $117K | Sell |
581
-254
| -30% | -$52.9K | ﹤0.01% | 3827 |
|
|
2018
Q4 | $156K | Buy |
+835
| New | +$177K | ﹤0.01% | 3461 |
|
|
2018
Q3 | – | Sell |
-19,059
| Closed | -$5.04M | – | 4264 |
|
|
2018
Q2 | $5.04M | Buy |
19,059
+16,091
| +542% | +$3.96M | 0.01% | 1815 |
|
|
2018
Q1 | $736K | Buy |
2,968
+2,415
| +437% | +$436K | ﹤0.01% | 2853 |
|
|
2017
Q4 | $75K | Buy |
+553
| New | +$67.7K | ﹤0.01% | 3695 |
|
|
2016
Q4 | – | Sell |
-1,438
| Closed | -$230K | – | 3717 |
|
|
2016
Q3 | $230K | Sell |
1,438
-1,068
| -43% | -$149K | ﹤0.01% | 2924 |
|
|
2016
Q2 | $304K | Buy |
+2,506
| New | +$480K | ﹤0.01% | 2719 |
|
Other funds holding SYRE
RI
FFM
PA
VA
VCM
DCM
PBA
Millennium Management's SYRE Position: Q1 2026 in Review
Millennium Management increased its Spyre Therapeutics (SYRE) stake by 92% in Q1 2026, buying an estimated $2.66M and bringing the position to 146,639 shares worth $7.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2501.
Millennium Management first reported a position in SYRE in Q2 2016 and has held it in 29 quarters since. The position peaked at $12.1M in Q1 2024. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.
- Millennium Management held 146,639 shares of Spyre Therapeutics worth $7.4M as of Q1 2026.
- Millennium Management bought 70,445 Spyre Therapeutics shares in Q1 2026, an estimated $2.66M.
- Spyre Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2501 holding.
- Millennium Management first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 29 quarters since.
- Millennium Management's Spyre Therapeutics position peaked at $12.1M in Q1 2024.
- 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.